The treatment of anemia in peritoneal dialysis patients.
The management of anemia in patients with end-stage renal disease (ESRD) treated with peritoneal dialysis (PD) has gained increasing attention over the past decade, similar to patients on hemodialysis (HD). However, there are many differences between the 2 renal replacement therapies that pose unique challenges and solutions for monitoring, diagnosis and treatment of anemia in PD patients. These differences are not always evident and may be the result of different patient selection, physical, emotional and motivational factors, specific requirements of the modality or an indeterminate blend of infinite gradations of all these factors. This review will highlight current issues in anemia management in PD patients.
Lacson
E
E
Diaz-Buxo
J A
JA
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000627:therapeutic use*; D007505:Iron-Dextran Complex / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D010530:Peritoneal Dialysis; D011994:Recombinant Proteins; D014168:Transferrin / Q000032:analysis
D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D007505:Iron-Dextran Complex; D005293:Ferritins; D007501:Iron